April 29th 2025
A pre-clinical study shows the antibiotic, piperacillin, was effective at much lower dosages than doxycycline, and did so without disrupting the gut microbiome.
Early-Stage Antibiotic for Bone and Joint Infections Comparable to Standard of Care Therapy
December 9th 2024A small phase 2 study evaluated Debiopharm’s investigational antibiotic, afabicin, including its clinical response rate and safety profile of 2-3 weeks of treatment for staphylococcal bone and joint infections (BJI).
Watch
More Bugs, No Drugs: The Growing Threat of Antibiotic Resistance
December 4th 2024Amesh A. Adalja, MD, FIDSA outlined the importance of recognizing antibiotic resistance in healthcare settings, educating patients on responsible antibiotic use, and the need for new treatments and diagnostic tools.
Watch
What's New In 2024: From the CLSI Subcommittee on Antimicrobial Susceptibility Testing
November 4th 2024The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.
Read More
Diagnostic Stewardship, Data Collection, and Incentives are Themes of UN General Assembly on AMR
October 10th 2024A holistic, multifaceted approach with a variety of stakeholders are needed to address antimicrobial resistance (AMR). The recent UN meeting on this topic looked to bring together government leaders, industry, and public health officials to discuss strategies regarding the global health crisis.
Watch
Evaluating Safety and Efficacy of Vaxart's Oral Vaccine's Impact on COVID-19 Variants
October 4th 2024Part 2 with James F Cummings, MD, as he discusses the need for a stronger response to emerging variants, the importance of protecting high-risk populations, and the potential to reduce vaccine hesitancy through easier administration.
Watch
Long-Acting Lipoglycopeptides for the Treatment of Severe Infections
September 19th 2024Long-acting lipoglycopeptides (LGPs) like dalbavancin, oritavancin, and telavancin were developed with extended half-lives, initially targeting acute bacterial skin and skin structure infections (ABSSSIs). However, recent studies have explored their potential in treating other infections, including infective endocarditis (IE), bone and joint infections (BJIs), and bloodstream infections (BSIs), offering an alternative to standard care and outpatient antimicrobial therapy.
Read More